Call for participating sites
We are looking for interested principal investigators and participating sites to join our global consortium that aims to characterize ICU COVID-19 patients.
This multi-country, multi-site study will describe the clinical characteristics of patients admitted to intensive care units with severe COVID-19, including their management, complications, and survival rates.
Primary objective: To describe clinical features; severity of pulmonary dysfunction; intensive care unit management and survival.
Type of study: Observational, Cohort study
Treatment tested: N/A
Number of sites: >350 sites across 6 continents
Sample size: N/A – Ongoing, unlimited recruitment
Study participants: Patients admitted to an Intensive Care unit with laboratory-confirmed or clinically-suspected infection by SARS-CoV-2
Study status: Recruiting
- Gianluigi Li Bassi: firstname.lastname@example.org
- Jacky Suen: email@example.com
- John Fraser: firstname.lastname@example.org
- Heidi Dalton: email@example.com
- Adrian Barnett: firstname.lastname@example.org
- Sally Shrapnel: email@example.com
- Study website
- Study ID: ACTRN12620000421932
- Trial registry: Australian Clinical Trials
Last updated: July 2020
Note that study-related documents posted on the COVID-19 Clinical Research Coalition (COVID-19 CRC) website have been shared by coalition members for information. Some may have been approved by Ethics Review Boards and others may still be in draft form. Documents posted here may have been further amended before being used in the conduct of the respective trials they were designed for. It is recommended that users review these documents carefully and, if they plan to use them, adapt them appropriately for their intended use. The COVID-19 CRC and its members cannot accept any liability for any claim, loss or damages as a result of any reliance placed on, or use of, these documents.